Novel erythropoiesis stimulating protein. Antianemic

Drugs of the Future

Volumn 25, Issue 3, 2000, Pages 246-248

  Cases, Aleix ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; ERYTHROPOIESIS; HUMAN; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0034009481     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.03.568297     Document Type: Review

References (11)

1. Foley, R.N., Parfrey, P.S., Harnett, J.D., Kent, G.M., Murray, D.C., Barre, P.E. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis 1996, 28: 53-61.
2. Eschbach, J.W., Adamson, J.W. Modern aspects of the pathophysiology of renal anemia. Contr Nephrol 1988, 66: 63-70.
3. Jelkmann, W. Renal erythropoietin: Properties and production. Rev Physiol Biochem Pharmacol 1986, 104: 140-215.
4. Lin, F.K., Suggs, S., Lin, C.H. et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985, 82: 7580-4.
5. Winearls, C.G., Oliver, D.O., Pippard, M.J., Reid, C., Downing, M.R., Cotes, P.M. Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic haemodialysis. Lancet 1986, 2: 1175-8.
6. Eschbach, J.W., Egrie, J.C., Downing, M.R., Browne, J.K., Adamson, J.W. Correction of anemia of end-stage renal disease with recombinant human erythropoietin. New Engl J Med 1987, 316: 73-8.
7. Egrie, J.C., Grabt, J.R., Gillies, D.K., Aoki, K.H., Strickland, T.W. The role of carbohydrate on the biological activity of erythropoietin. Glycoconjugate J 1993; 10: 263A.
8. Egrie, J.C., Dwyer, E., Lykos, M., Hitz, A., Browne, J.K. Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity compared to recombinant human erythropoietin. Blood 1997, 90(10, Suppl. 1, Part 1): Abst 243.
9. Macdougall, I.C., Gray, S.J., Elston, O., Breen, C., Jenkins, B., Browne, J., Egrie, J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999, 10: 2392-5.
10. Macdougall, I.C. Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anemia. J Am Soc Nephrol 1998, 9: Abst A1317.
11. Vanrenterghem, P., Barany, J., Mann, J. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (Hgb) in ESRD patients when administered once weekly or once every other week. 32nd Annu Meet Am Soc Nephrol (Nov 5-8, Miami Beach) 1999, Abst A1365.